公开(公告)号：US20220348928A1

公开(公告)日：2022-11-03

申请号：US17626768

申请日：2020-07-16

Applicant: CUROCELL INC. ,  KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Gun Soo KIM ,  Mi Kyung KIM ,  Chan Hyuk KIM ,  Young-Ho LEE ,  HyeongJi LEE

IPC: C12N15/113 ,  C07K14/725 ,  C07K14/705 ,  C07K16/28 ,  A61K35/17 ,  A61P35/00

Abstract: The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present invention generally relates to an immune cell comprising a genetically engineered antigen receptor that specifically binds to a target antigen and a genetic disruption agent that reduces or is capable of reducing the expression in the immune cell of two genes that weaken the function of the immune cell.

公开(公告)号：US20230167184A1

公开(公告)日：2023-06-01

申请号：US17908823

申请日：2021-03-15

Applicant: CUROCELL INC. ,  EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION

Inventor： Hyunbo SHIM ,  Hyung Cheol KIM ,  Mi Kyung KIM

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2878 ,  A61P35/00 ,  C07K2317/565 ,  C07K2319/02 ,  C07K2319/03

Abstract: An embodiment relates to an anti-BCMA-binding protein and, more specifically, provides an isolated BCMA-binding protein comprising an antigen-binding domain that binds specifically to BCMA, wherein the antigen-binding domain comprises: i) heavy chain variable domain complementarity determining region 1 (VH-CDR1) comprising the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 80% homology to SEQ ID NO: 1; ii) VH-CDR2 comprising the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having at least 80% homology to SEQ ID NO: 2; and iii) VH-CDR3 comprising the amino acid sequence of SEQ ID NO: 3 or an amino acid sequence having at least 80% homology to SEQ ID NO: 3.